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Abstract: 
Introduction 
Grapefruit juice can increase or decrease the systemic exposure of myriad oral medications, 
leading to untoward effects or reduced efficacy. Furanocoumarins in grapefruit juice have been 
established as inhibitors of cytochrome P450 3A (CYP3A)-mediated metabolism and P-
glycoprotein (P-gp)-mediated efflux, while flavonoids have been implicated as inhibitors of 
organic anion transporting polypeptide (OATP)-mediated absorptive uptake in the intestine. The 
potential for drug interactions with a food product necessitates an understanding of the expected 
concentrations of a suite of structurally diverse and potentially bioactive compounds. 
Objective 
Develop methods for the rapid quantitation of two furanocoumarins (bergamottin and 6′,7′-
dihydroxybergamottin) and four flavonoids (naringin, naringenin, narirutin and hesperidin) in 
five grapefruit juice products using ultra-performance liquid chromatography (UPLC). 
Methods 
Grapefruit juice products were extracted with ethyl acetate; the concentrated extract was 
analysed by UPLC using acetonitrile:water gradients and a C18-column. Analytes were detected 
using a photodiode array detector, set at 250 nm (furanocoumarins) and 310 nm (flavonoids). 
Intraday and interday precision and accuracy and limits of detection and quantitation were 
determined. 
Results 
Rapid (< 5.0 min) UPLC methods were developed to measure the aforementioned 
furanocoumarins and flavonoids. R2 values for the calibration curves of all analytes were >0.999. 
Considerable between-juice variation in the concentrations of these compounds was observed, 
and the quantities measured were in agreement with the concentrations published in HPLC 
studies. 
Conclusion 
These analytical methods provide an expedient means to quantitate key furanocoumarins and 
flavonoids in grapefruit juice and other foods used in dietary substance–drug interaction studies. 
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Article: 
Introduction 
Grapefruit juice has been shown to increase the systemic exposure of a diverse array of oral 
medications that undergo extensive pre-systemic metabolism by cytochrome P450 3A (CYP3A) 
in the intestine, including felodipine, lovastatin and cyclosporine (Paine et al., 2006; Seden et 
al., 2010; Hanley et al., 2011; Won et al., 2012). The increase in systemic drug exposure can be 
sufficient to cause untoward effects, ranging from relatively mild (e.g. hypotension and dizziness 
with some calcium channel blockers) to potentially severe (e.g. nephrotoxicity with some 
immunosuppressants). The mechanism underlying these interactions is irreversible inhibition of 
intestinal CYP3A activity by grapefruit juice (Bailey et al., 1998; Paine et al., 2006; Paine and 
Oberlies, 2007; Hanley et al., 2011). Furanocoumarins, a class of compounds present in 
grapefruit juice, have been established as major CYP3A inhibitors in human volunteers (Paine et 
al.,2006). This effect may be augmented if the ‘victim’ drug also is a substrate for P-glycoprotein 
(P-gp), a transmembrane efflux transport protein located on the apical membranes of numerous 
cell types, including enterocytes (Paine and Oberlies, 2007; Hanley et al., 2011). P-glycoprotein 
demonstrates substrate specificity that overlaps with that of CYP3A substrates (Wacher et 
al., 1995), and several in vivo andin vitro studies have shown an inhibitory effect by grapefruit 
juice and/or furanocoumarins towards P-gp activity (Lown et al., 1997; Edwards et al., 1999; 
Ohnishi et al., 2000; De Castro et al., 2007; Paine et al., 2008; Dahan and Amidon, 2009). A 
more recently discovered mechanism underlying grapefruit juice–drug interactions is inhibition 
of intestinal organic anion transporting polypeptides (OATPs), which are uptake transporters 
located on the apical membranes of enterocytes and other cell types (Dresser and Bailey, 2003; 
Won et al., 2012). Opposite to P-gp, OATPs in the intestine act to facilitate drug absorption. 
Thus, inhibition of these transport proteins leads to a decrease in systemic exposure of drug 
substrates, including the anti-histamine fexofenadine (Dresser and Bailey, 2003; Dresser et 
al., 2005) and the anti-hypertensive agent aliskiren (Vanamala et al., 2005; Avula et al., 2007), 
with the consequent potential for therapeutic failure. Candidate OATP inhibitors in grapefruit 
juice include the flavonoids naringin and hesperidin (Bailey et al., 2007). The potential for drug 
interactions with a widely available food product necessitates an understanding of the expected 
concentrations of a suite of structurally diverse and potentially bioactive compounds. 
Reported analytical methods for measuring furanocoumarins in fruit juices typically require 
separation times of 1 h or more (Fukuda et al.,2000; Ross et al., 2000; Manthey and 
Buslig, 2005; Vanamala et al., 2005; De Castro et al., 2006; Avula et al., 2007). For example, in 
2005, a study of the distribution of furanocoumarins in grapefruit juice fractions utilised a 65 min 
high-performance liquid chromatography (HPLC) method (Manthey and Buslig, 2005). The 
same year, an exhaustive analysis of several furanocoumarins and furanocoumarin dimers in 58 
juices employed a similar 65 min method (Widmer and Huan, 2005). The following year, a 
45 min HPLC method was utilised to determine the concentrations of bergamottin and 6′,7′-
dihydroxybergamottin in grapefruit juice (De Castro et al., 2006). In 2009, a shorter HPLC 
method was developed for the determination of five furanocoumarins (bergaptol, psoralen, 
bergapten, bergamottin and 6′,7′-dihydroxybergamottin) in citrus juices that required a run time 
of 23 min, which appears to be the most rapid method published to date (Linet al., 2009). 
As with the furanocoumarins, analytical procedures for measuring flavonoids often employ 
methods of 1 h or more. A survey of nine commercial grapefruit juices and associated flavonoid 
concentrations published in 2000 utilised a 60 min method (Ross et al., 2000). Six years later, a 
65 min method in a similar survey of orange and grapefruit juices was published (Vanamala et 
al., 2005), followed the next year by another 60 min method for the simultaneous analysis of 
adrenergic amines and flavonoids in fruit jams and juices (Avula et al.,2007). De Castro et al. 
(2006) utilised a 70 min separation to determine the concentrations of naringin and naringenin. 
The most rapid HPLC analyses of flavonoids reported in the literature was a 45 min method 
published in 2008 (Fujita et al., 2008). 
A handful of UPLC analyses of flavonoids in food, supplements and traditional Chinese 
medicines have appeared in the literature in the past few years as well. The majority of these 
studies (Baranowska and Magiera, 2011; Medina-Remon et al., 2011; Cao et al., 2012; Huang et 
al., 2012) utilise a C18-column and UV detection, though one expansive study quantifying 39 
phenolic compounds in apples (De Paepe et al., 2013) additionally used electrospray ionisation 
mass spectrometry (ESI-MS) to confirm the identity of the analytes. The most rapid of these 
UPLC studies quantified 11 flavonoids (including those listed in this paper) in three citrus fruit 
extracts, and had a run time of 5.5 min (Cao et al., 2012). 
Ultra performance liquid chromatography offers significant advantages in sensitivity and speed 
compared with HPLC. After overcoming the difficulties presented by working with very high 
pressures (MacNair et al., 1997, 1999; Wu et al., 2001), early studies demonstrated enhanced 
resolution and sensitivity, reduced solvent consumption and rapid analyses (Gerber et al., 2004; 
Swartz, 2005; Kumar et al.,2012) with UPLC compared with that which can be achieved with 
HPLC. With greater integration in diverse research areas, UPLC offers the opportunity to 
streamline quantitative determinations, such as those described herein, reducing cost and 
expediting research. 
The goal of this study was to develop rapid (< 5.0 min) methods for the quantitation of two 
furanocoumarins (bergamottin and 6′,7′-dihydroxybergamottin) and four flavonoids (naringin, 
naringenin, narirutin, and hesperidin) in grapefruit juice using UPLC (Fig. 1). An additional goal 
was to apply these methods to determine the concentrations of the aforementioned analytes in 
five grapefruit juices used in previous clinical interaction studies. 
 
Figure 1. Structures of the furanocoumarins bergamottin (1) and 6′,7′-dihydroxybergamottin (2) 
and the flavonoids naringin (3), narirutin (4), naringenin (5) and hesperidin (6). 
Experimental 
Instrumentation 
The UPLC analyses were performed using a Waters Acquity UPLC system (Milford, MA, USA) 
equipped with an autosampler, photodiode array detector (PDA), column manager and binary 
solvent manager. Data were collected and analysed using Empower software. A HSS C18-column 
(50 mm × 2.1 mm i.d., 1.8 µm; Waters, Milford, MA, USA) was used for all chromatographic 
analyses. 
Materials 
Bergamottin (purity ≥ 96.9%) was purchased from ChromaDex (Irvine, CA, USA); narirutin 
(purity ≥ 99.0%) was purchased from Indofine (Hillsborough, NJ, USA); naringin 
(purity ≥ 96.8%), naringenin (purity ≥ 99.9%), hesperidin (purity ≥ 97.0%) and 6′,7′-
dihydroxybegamottin (purity ≥ 97.2%) were purchased from Sigma-Aldrich (St Louis, MO, 
USA). Purity of standards are reported as determined by HPLC by the manufacturers. Methanol, 
ethyl acetate and acetonitrile were purchased from Pharmco-Aaper (Shelbyville, KY, USA). 
Juices A and B were used in clinical studies with felodipine (Paine et al., 2006), cyclosporine 
(Paine et al., 2008) and fexofenadine (Won et al., 2010). Juice A was a commercially available 
product. Juice B was the same juice, but the furanocoumarin fractions were removed using a 
series of food-grade solvents and absorption resins and column chromatography (Paine et 
al., 2006). Juice C was a commercially available concentrated grapefruit juice (Minute Maid 
Premium 100% Pure Frozen Concentrated Grapefruit Juice with added calcium). A dilution of 
Juice C was used in a clinical study examining the effect of grapefruit juice on the systemic 
exposure of loperamide and the CYP3A-mediated metabolite, desmethylloperamide (Wolf et 
al., 2011). Juice D (Florida's Natural Original Ruby Red 100% Pure Florida Grapefruit Juice) 
and Juice E (Simply Orange Juice Co. Simply Grapefruit 100% Pure Squeezed Grapefruit Juice) 
were commercially available not-from-concentrate juices and were purchased from a local 
grocery store. 
Standards preparation 
Bergamottin and 6′,7′-dihydroxybergamottin were dissolved in methanol to produce a 
1.03 mm (bergamottin) and 1.00 mm (6′,7′-dihydroxybergamottin) multi-standard stock solution. 
This solution was used to prepare seven standard solutions at concentrations ranging from 10.3 
to 659 µm (bergamottin) and from 10.0 to 640 µm (6′,7′-dihydroxybergamottin). Naringin, 
narirutin, naringenin and hesperidin were dissolved separately in methanol to produce stock 
solutions of 10.0 mm, 7.92 mm, 10.2 mm and 9.97 mm, respectively. These stock solutions were 
used to prepare standard solutions for each compound (six for naringin, five for each of the other 
flavonoids) at concentrations ranging from 0.649 to 5.00 mm (naringin), 0.198 to 
3.17 mm (narirutin), 3.18 to 814 µm (naringenin) and 3.12 to 798 µm(hesperidin). 
Sample preparation 
Juice extracts were prepared by transferring 25.0 mL of each juice to a 50 mL conical 
polypropylene tube. After adding 20.0 mL of ethyl acetate, the contents were shaken vigorously 
and centrifuged (2500 × g for 30 min at 25°C). The resulting organic layer was transferred by 
Pasteur pipette to a 250 mL round-bottom flask. An additional 20.0 mL of ethyl acetate were 
added to the remaining contents of the tube, shaken and centrifuged, and the resultant organic 
layer was combined with the first organic layer. This extraction procedure was repeated a third 
time, and the combined organic layers were evaporated in vacuo. The residue in the round-
bottom flask was transferred quantitatively to a 2 mL vial, using methanol as a rinse, and 
evaporated to dryness under air. This material was resuspended with 5.00 mL of methanol, 
yielding a fivefold concentrated extract of each juice. 
Chromatographic conditions 
Quantitative analysis of furanocoumarins (bergamottin and 6′,7′-dihydroxybergamottin) 
A 6 μL volume of each fivefold concentrated juice extract was injected and analysed at a 
wavelength of 250 nm. Chromatographic separations were carried out with a mobile phase 
consisting of HPLC-grade acetonitrile (solvent A) and nanopure water (solvent B) at a flow rate 
of 0.6 mL/min. The following linear gradient was used: 0.0 min, 30% A; 4.0 min, 100% A; 
4.5 min, 100% A. The column temperature was 30°C. 
Quantitative analysis of flavonoids (naringin, narirutin, naringenin and hesperidin) 
A 6 μL volume of each fivefold concentrated juice extract was injected and analysed at a 
wavelength of 310 nm. The following linear gradient was used: 0.0 min, 10% A; 1.0 min, 20% 
A; 2.0 min, 20% A; 2.5 min, 40% A; 3.5 min, 100% A; 4.0 min, 100% A. Solvents A and B, the 
flow rate and column temperature were the same as described in the previous section. 
Method validation 
The identities of analyte peaks in the juice extracts were confirmed by comparing the UV spectra 
of the peaks and their standards, as well as, in the case of the flavonoids, by co-injection of the 
standards with the juices (see online Supporting Information, Supplements 1 and 2). 
Linearity of the calibration curves was assessed by least-squares analysis. Precision and accuracy 
were determined by calculating the relative standard deviation (RSD) and relative error (RE), 
defined as the percentage difference between the mean observed concentration and the nominal 
concentration, of three replicate analyses of the standards. All analyses were performed in 
triplicate in a single day. Interday RSD and RE were determined by analysing the standard 
solutions in triplicate on three separate days. The limit of detection (LOD) was defined as the 
concentration corresponding to the signal detection limit, which was defined as b + 3sy, 
where b is the y-intercept of the calibration curve, and sy is the standard deviation of the vertical 
deviations (Harris, 2007). The limit of quantitation (LOQ) was defined as b + 10sy. 
Results and discussion 
Method validation 
All standard curves exhibited coefficients of determination (r2) greater than 0.999 (Table 1). 
Baseline resolution of all analytes (Fig. 1), both as standards and in the juice extracts, was 
achieved (Figs 2 and 3). Precision and accuracy data are summarised in Table 2. The RSD of the 
furanocoumarin standards (1 and 2) was below 0.33% (intraday) and 3.1 % (interday) for all 
standard concentrations. The intraday RSD values of analytes 3, 4 and 5 were below 1.5%, 2.6% 
and 2.9%, respectively, while the interday RSD averages for each analyte remained below 1.0%. 
For analyte 6, the largest RSD value was 4.7% at the lowest concentration of that standard, while 
the interday RSD was 3.1%. For the furanocoumarins (1 and 2), intraday RE remained below 
5.7% (1) and 2.8% (2). Interday RE values predominantly remained under 3.0%, except for the 
lowest concentrations of 1 and 2, the highest variation being 21% for the lowest concentration 
of 1. The RE values (both intraday and interday) of the flavonoids (3–6) were predominantly 
below 5%, and all below 15%. The only exception was the lowest of the standard concentrations 
of 5 (3.18 µm), which had much higher RE values (32%); thus, this concentration was below the 
LOQ as defined above. For each analyte measured, all standard concentrations above the LOQ 
resulted in an RE value of ≤ 15%. The LOD values for analytes 1, 2, 5 and 6 were all below 
5 µm, whereas the LOD values for analytes 3 and 4 were higher (18 and 69 µm, respectively). 
Table 1. Calibration curve data for analytes 1–6 
Analyte Slope (±SD) r2 LOD (μm) LOQ (μm) 
1. LOD, limit of detection; LOQ, Limit of quantitation. 
1 4.338 × 103 (±9) 1.000 0.78 2.6 
2 3.784 × 103 (±5) 1.000 1.1 3.8 
3 9.04 × 102 (±7) 0.999 69 230 
4 9.98 × 102 (±7) 0.999 18 58 
5 1.626 × 103 (±6) 1.000 2.5 8.4 
6 8.95 × 102 (±5) 1.000 3.9 13 
 
 
Figure 2. The UPLC separation of furanocoumarins. Numbered peaks correspond to the 
compounds in Fig. 1: (A) furanocoumarin standards (659 and 640 µm, respectively) and (B) 
Juice A. 
 
Figure 3. The UPLC separation of flavonoids. Numbered peaks correspond to the compounds in 
Fig. 1: (A) flavonoid standards (1080, 500, 800 and 800 µm, respectively) and (B) Juice A. 
Table 2. Precision (RSD) and accuracy (RE) for analysis of analytes 1–6 
Analytes Concentration of standard solution injected (μm) 
Intraday Interday 
RSD 
(%) 
RE 
(%) 
RSD 
(%) 
RE 
(%) 
1 
10.3 0.33 5.7 3.1 21. 
20.6 0.27 4.4 0.48 8.5 
41.2 0.091 1.6 0.31 2.4 
Analytes Concentration of standard solution injected (μm) 
Intraday Interday 
RSD 
(%) 
RE 
(%) 
RSD 
(%) 
RE 
(%) 
82.4 0.19 0.21 0.53 1.1 
165 0.16 0.03 0.26 2.1 
330 0.29 1.2 0.16 0.83 
659 0.32 0.29 0.32 0.33 
2 
10 0.15 2.8 1.2 9.2 
20 0.11 1.1 0.67 2.7 
40 0.017 0.94 0.62 0.69 
80 0.21 0.10 0.56 2.1 
160 0.16 0.64 0.59 2.5 
320 0.26 0.70 0.61 2.1 
640 0.31 0.13 0.53 1.4 
3 
649 1.5 15. 0.84 17. 
1081 1.3 4.6 0.14 5.7 
1802 1.1 0.81 0.38 0.79 
3003 0.36 3.3 0.45 3.0 
5005 0.72 3.6 0.29 2.1 
10010 0.99 1.0 0.28 1.9 
Analytes Concentration of standard solution injected (μm) 
Intraday Interday 
RSD 
(%) 
RE 
(%) 
RSD 
(%) 
RE 
(%) 
4 
198 1.6 13. 0.67 7.7 
396 2.6 1.4 0.72 2.1 
792 1.5 1.6 0.43 1.3 
1584 1.3 2.5 0.26 2.0 
3168 0.72 0.66 0.78 0.55 
5 
3.18 1.4 32. 0.03 32. 
12.7 2.9 9.7 0.32 5.3 
50.9 1.4 0.4 0.23 1.4 
203 0.23 1.6 0.35 0.66 
814 1.2 0.094 0.18 0.39 
6 
3.12 4.7 2.4 3.1 3.7 
12.5 0.64 2.8 0.96 8.3 
49.9 0.93 3.5 0.69 9.0 
199 0.71 4.1 0.47 8.1 
798 1.6 3.0 0.72 1.4 
Rapidity of method 
Compared with HPLC analyses of furanocoumarins and flavonoids in the literature, the UPLC 
method described above markedly reduces the time required for the analyses of these compounds 
in grapefruit juice. A run time of 4.5 min represents an 80% reduction in the time required to 
analyse furanocoumarin content when compared with the most rapid published method (Lin et 
al., 2009), whereas a run time of 4.0 min represents an order of magnitude less time required for 
the analysis of flavonoids (Fujita et al., 2008). Such methods facilitate the determination of 
furanocoumarin and flavonoid concentrations in several grapefruit juices in a single day, 
reducing costs associated with both labour and materials. Moreover, the time saved expedites the 
characterisation of juices used in in vitro or in vivo studies, thus accelerating the evaluation and 
determination of active constituents. 
Concentrations of analytes in grapefruit juices 
Five different grapefruit juices, four of which were commercially available products, were 
analysed to measure the concentrations of selected furanocoumarins and flavonoids (Fig. 1). 
Samples were analysed in the same run with the standards to eliminate concerns of systematic 
error introduced by day-to-day variability in instrument response. Each juice was analysed using 
a fivefold concentrated extract, and the reported values (Table 3) have been adjusted to reflect 
the concentration in the original juices. Considerable variation in the concentration of each 
compound was observed. Regarding the furanocoumarins, the concentrations of 1 and 2 in four 
of the juices ranged from 7.48 (±0.17) to 24.73 (±0.16) μm and 7.65 (±0.17) to 89.03 (±0.17) 
μm, respectively. These values were consistent with those reported in the literature using HPLC 
(Widmer and Huan, 2005; De Castro et al., 2006). The highest concentration of 2 (Juice C) was 
slightly higher than the ranges reported by De Castro et al. (2006), though this was to be 
expected, as Juice C was a juice concentrate. Regarding the flavonoids, the concentrations 
of 3 and 4 ranged from 309 (±15) to 1182 (±16) μm and 73.4 (±4.8) to 286.5 (±3.8) μm, 
respectively, which again were consistent with literature values using HPLC (Ross et al., 2000; 
De Castro et al., 2006). The concentration of 6 ranged from below LOQ (although detected in all 
juices) to 39.48 (± 0.83) μm. The concentration of 5 ranged from below LOQ to 34.72 (±0.55) 
μm, which agrees with literature values (Wilson et al., 2000; Wanwimolruk and Marquez, 2006). 
As with the furanocoumarins, the highest concentrations of the flavonoids were in Juice C. The 
concentrations of 1–4 in Juices A and B were measured previously using an HPLC method 
(Paine et al., 2006; Won et al., 2010). The concentration of the furanocoumarins (1 and 2) were 
consistent between methods (within 30 and 7%, respectively), whereas the concentrations of the 
flavonoids (3 and 4) by HPLC were approximately twofold higher than those by UPLC. Reasons 
for this difference remain unexplored, as a between-laboratory validated study was beyond the 
scope of this work. The extracts used in this study were analysed at a fivefold concentration. In 
the future, the accuracy of the measurements for analytes present in very low concentrations 
could be improved by using a more concentrated extract. 
Table 3. Concentrations of analytes 1–6 in grapefruit juices 
Juice Concentrationa (μm) ± SD 
Bergamottin 
(1) DHB
b (2) Naringin (3) 
Narirutin 
(4) 
Naringenin 
(5) 
Hesperidin 
(6) 
 A 11.76 ± 0.16 41.31 ± 0.16 412 ± 15 100.5 ± 4.5 18.89 ± 0.66 NQ 
B ND ND 309 ± 15 73.4 ± 4.8 ND NQ 
C 24.73 ± 0.16 89.03 ± 0.17 1182 ± 16 286.5 ± 3.8 34.72 ± 0.55 39.48 ± 0.83 
D 7.48 ± 0.17 7.65 ± 0.17 371 ± 15 85.2 ± 4.7 NQ NQ 
E 12.26 ± 0.16 11.58 ± 0.16 381 ± 15 103.5 ± 4.5 5.60 ± 0.79 NQ 
ND, not detected; NQ, the analyte was detected but was below the limit of quantitation. 
a Each juice was analysed in triplicate using a fivefold concentrated extract, and the values 
reported have been adjusted to reflect the concentration in the juices, not in the extract. 
b 6′,7′-dihydroxybergamottin. 
Wide between-juice variation in the concentrations of each grapefruit juice constituent was 
observed, as would be expected for natural products, and the concentrations agreed well with 
values reported in the literature using HPLC. This marked variation between commercially 
available brands undoubtedly contributes to the large between-study differences in effect size 
(i.e., change in drug area under the curve [AUC]) associated with clinical grapefruit juice–drug 
interaction studies (Won et al., 2012). Quantitation of one or more constituents in a given juice 
would provide a means for between-study comparisons of clinical, as well as in vitro, data. The 
UPLC methods developed in the current work offer a rapid means for the quantitation of 
representative constituents. While the methods were applied to grapefruit juices, they should be 
applicable to other foods, including other fruit juices. 
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